Disease-modifier Drugs in Patients with Advanced Heart Failure How to Optimize Their Use?

被引：2

作者：

Iacoviello, Massimo ^{[1
]}

Vitale, Enrica ^{[1
]}

Corbo, Maria Delia ^{[1
]}

Correale, Michele ^{[1
]}

Brunetti, Natale Daniele ^{[1
]}

机构：

[1] Univ Foggia, Dept Med & Surg Sci, Cardiol Unit, Viale Luigi Pinto 1, Foggia, Italy

来源：

HEART FAILURE CLINICS | 2021年 / 17卷 / 04期

关键词：

Advanced heart failure; Therapy; Prognosis; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED INTERVENTION TRIAL; CONVERTING-ENZYME-INHIBITORS; FOLLOW-UP; CARDIOVASCULAR OUTCOMES; NEPRILYSIN INHIBITION; SACUBITRIL/VALSARTAN LCZ696; MEDICATION ADHERENCE; EJECTION FRACTION; SGLT2; INHIBITORS;

D O I：

10.1016/j.hfc.2021.05.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：561 / 573

页数：13

共 102 条

[31] Empagliflozin in Heart Failure Diuretic and Cardiorenal Effects [J].

Griffin, Matthew ;

Rao, Veena S. ;

Ivey-Miranda, Juan ;

Fleming, James ;

Mahoney, Devin ;

Maulion, Christopher ;

Suda, Nisha ;

Siwakoti, Krishmita ;

Ahmad, Tariq ;

Jacoby, Daniel ;

Riello, Ralph ;

Bellumkonda, Lavanya ;

Cox, Zachary ;

Collins, Sean ;

Jeon, Sangchoon ;

Turner, Jeffrey M. ;

Wilson, F. Perry ;

Butler, Javed ;

Inzucchi, Silvio E. ;

Testani, Jeffrey M. .

CIRCULATION, 2020, 142 (11) :1028-1039

[32] Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [J].

Hallow, Karen M. ;

Helmlinger, Gabriel ;

Greasley, Peter J. ;

McMurray, John J. V. ;

Boulton, David W. .

DIABETES OBESITY & METABOLISM, 2018, 20 (03) :479-487

[33] Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System [J].

Han, Jamie ;

Chung, Francisco ;

Nguyen, Quyen L. ;

Mody, Freny Vaghaiwalla ;

Jackevicius, Cynthia A. .

PHARMACOTHERAPY, 2019, 39 (11) :1053-1059

[34] Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial [J].

Haynes, Richard ;

Judge, Parminder K. ;

Staplin, Natalie ;

Herrington, William G. ;

Storey, Benjamin C. ;

Bethel, Angelyn ;

Bowman, Louise ;

Brunskill, Nigel ;

Cockwell, Paul ;

Hill, Michael ;

Kalra, Philip A. ;

McMurray, John J. V. ;

Taal, Maarten ;

Wheeler, David C. ;

Landray, Martin J. ;

Baigent, Colin .

CIRCULATION, 2018, 138 (15) :1505-1514

[35] Dapagliflozin in Patients with Chronic Kidney Disease [J].

Heerspink, Hiddo J. L. ;

Stefansson, Bergur V. ;

Correa-Rotter, Ricardo ;

Chertow, Glenn M. ;

Greene, Tom ;

Hou, Fan-Fan ;

Mann, Johannes F. E. ;

McMurray, John J. V. ;

Lindberg, Magnus ;

Rossing, Peter ;

Sjostrom, C. David ;

Toto, Roberto D. ;

Langkilde, Anna-Maria ;

Wheeler, David C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1436-1446

[36] Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease [J].

Heerspink, Hiddo J. L. ;

Perco, Paul ;

Mulder, Skander ;

Leierer, Johannes ;

Hansen, Michael K. ;

Heinzel, Andreas ;

Mayer, Gert .

DIABETOLOGIA, 2019, 62 (07) :1154-1166

[37] Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure -: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) [J].

Hjalmarson, Å ;

Goldstein, S ;

Fagerberg, B ;

Wedel, H ;

Waagstein, F ;

Kjekshus, J ;

Wikstrand, J ;

El Allaf, D ;

Vítovec, J ;

Aldershvile, J ;

Halinen, M ;

Dietz, R ;

Neuhaus, KL ;

Jánosi, A ;

Thorgeirsson, G ;

Dunselman, PHJM ;

Gullestad, L ;

Kuch, J ;

Herlitz, J ;

Rickenbacher, P ;

Ball, S ;

Gottlieb, S ;

Deedwania, P .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10) :1295-1302

[38]

Hjalmarson Å, 1999, LANCET, V353, P2001

[39] Medication Adherence Its Importance in Cardiovascular Outcomes [J].

Ho, P. Michael ;

Bryson, Chris L. ;

Rumsfeld, John S. .

CIRCULATION, 2009, 119 (23) :3028-3035

[40] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial [J].

Inzucchi, Silvio E. ;

Zinman, Bernard ;

Fitchett, David ;

Wanner, Christoph ;

Ferrannini, Ele ;

Schumacher, Martin ;

Schmoor, Claudia ;

Ohneberg, Kristin ;

Johansen, Odd Erik ;

George, Jyothis T. ;

Hantel, Stefan ;

Bluhmki, Erich ;

Lachin, John M. .

DIABETES CARE, 2018, 41 (02) :356-363

← 1 2 3 4 5 6 7 8 9 10 →